Chemistry:Valemetostat
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Ezharmia |
| Other names | Valemetostat tosilate (JAN); DS-3201; DS-3201b |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C26H34ClN3O4 |
| Molar mass | 488.03 g·mol−1 |
Valemetostat (trade name Ezharmia) is a drug used for the treatment of adult T-cell leukemia/lymphoma (ATL).
Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2), which are implicated in the etiology of some forms of cancer including non-Hodgkin lymphomas.[1][2]
In Japan, valemetostat was approved in September 2022 for patients with relapsed or refractory adult T-cell leukemia/lymphoma.[3][4]
References
- ↑ "First‐In‐Human Study of the Ezh1 and Ezh2 Dual Inhibitor Valemetostat Tosylate (Ds‐3201B) in Patients with Relapsed or Refractory Non‐Hodgkin Lymphomas". Hematological Oncology 39. 2021. doi:10.1002/hon.14_2879.
- ↑ "First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)". Blood 134: 4025. 2019. doi:10.1182/blood-2019-125507.
- ↑ "Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma". Drug Discoveries & Therapeutics. October 2022. doi:10.5582/ddt.2022.01085. PMID 36310058.
- ↑ "Japan Green Lights Valemetostat Tosilate for Relapsed/Refractory Adult T-cell Leukemia/Lymphoma". OncLive. September 26, 2022. https://www2.onclive.com/view/japan-green-lights-valemetostat-tosilate-for-relapsed-refractory-adult-t-cell-leukemia-lymphoma.
 |  |
